What this study adds
- Iberdomide and major metabolite (M12) show robust PK exposure, not
complicated by demographic factors, combination, hepatic or (mild and
moderate) renal impairments
- M12 PK tracked the PK of iberdomide. The metabolite to parent ratio
was consistent across doses and combinations
- Results should inform iberdomide dosing strategy and study design